BioGaia AB Series B | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
81,653.00
196,883.00
152,184.00
194,275.00
233,833.00
277,359
Depreciation, Depletion & Amortization
5,541.00
5,652.00
6,548.00
7,074.00
6,573.00
7,546
Other Funds
-
5.00
-
-
2,398.00
51,577
Funds from Operations
81,276.00
135,881.00
110,061.00
155,307.00
191,081.00
233,328
Changes in Working Capital
2,835.00
11,498.00
7,440.00
7,378.00
31,534.00
50,208
Net Operating Cash Flow
78,441.00
124,383.00
117,501.00
147,929.00
222,615.00
183,120
Capital Expenditures
16,634.00
24,481.00
27,930.00
5,611.00
26,624.00
Sale of Fixed Assets & Businesses
6.00
-
-
-
-
Purchase/Sale of Investments
29,910.00
4,000.00
4,000.00
4,000.00
-
Net Investing Cash Flow
46,538.00
28,481.00
31,930.00
9,611.00
26,643.00
Cash Dividends Paid - Total
172,710.00
120,897.00
86,355.00
124,311.00
130,023.00
Net Financing Cash Flow
172,710.00
120,892.00
70,511.00
124,311.00
132,421.00
Net Change in Cash
140,703.00
23,605.00
16,216.00
16,187.00
62,787.00
Free Cash Flow
61,807.00
105,977.00
99,721.00
142,318.00
195,991.00
Change in Capital Stock
-
-
15,844.00
-
-
Exchange Rate Effect
104.00
1,385.00
1,156.00
2,180.00
764.00
Other Uses
-
-
-
-
19.00

About BioGaia AB

View Profile
Address
Kungsbroplan 3
Stockholm AB 112 27
Sweden
Employees -
Website http://www.biogaia.com
Updated 07/08/2019
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment is comprised of sales of drops, oral rehydration solutions (ORS), digestive health tablets and also cultures as an ingredient in a licensee's products, as well as royalties pertaining to pediatric products.